Esperion Sees Positive Results From Final Study On Cholesterol-Buster
ANN ARBOR — Esperion Therapeutics Inc., the Ann Arbor-based pharmaceutical developer, announced positive results from the final Phase 3 test of its lead drug candidate, bempedoic acid. The company said a global, pivotal Phase 3 clinical study (Study 1002-047) showed that a dose of 180 milligrams per day of the drug showed additional lowering of

